18 148
References
[1]
Albertsen PC. Observational studies and the natural history of screen-detected prostate cancer. Curr Opin Urol 2015;25:232–7.
[2]
Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis and local treatment with curative intent. Eur Urol 2017;71:618–29.
[3]
Institute of Medicine. Initial national priorities for comparative effectiveness research. Washington, DC: National Academies Press; 2009.[4]
Food and Drug Administration. Guidance for industry. Clinical trial endpoints for the approval of cancer drugs and biologics. Rockville, MD: US Department of Health and Human Services; 2007.
[5]
Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL. Deter- mining cause of death in prostate cancer: are death certificates valid? J Natl Cancer Inst 2001;93:1822–3.
[6]
Stephenson AJ, KattanMW, Eastham JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006;24: 3973–8.
[7]
D’Amico AV, Chen MH, de Castro M, et al. Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and andro- gen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncol 2012;13:189–95.
[8]
Krahn MD, Bremner KE, Luo J, Alibhai SM. Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events. Curr Oncol 2014;21:e457–65.
[9]
Wallis CJ, Cheung P, Herschorn S, et al. Complications following surgery with or without radiotherapy or radiotherapy alone for prostate cancer. Br J Cancer 2015;112:977–82.
[10]
Boorjian SA, Thompson RH, Tollefson MK, et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol 2011;59:893–9.[11]
Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommen- dations for a standard in the reporting of surgical outcomes. J Urol 2007;177:540–5.
[12]
Nielsen ME, Makarov DV, Humphreys E, Mangold L, Partin AW, Walsh PC. Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion— ‘‘nadir + 2 ’’? Urology 2008;72:389–93.[13]
Lee BH, Kibel AS, Ciezki JP, et al. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation ther- apy? Analysis of prostate cancer-specific mortality by nomo- gram-predicted risks of biochemical recurrence. Eur Urol 2015;67:204–9.
[14]
Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014;370:932–42.[15]
Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203–13.[16]
Paulson DF, Lin GH, HinshawW, Stephani S. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 1982;128:502–4.
[17]
Hamdy FC, Donovan JL, Lane JA, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016;375:1415–24.[18] Wallis CJ, Nam RK. The optimal treatment of patients with localized
prostate cancer: the debate rages on.
www.bjuinternational.com/ bjui-blog/the-optimal-treatment-of-patients-with-localized-pros- tate-cancer-the-debate-rages-on .[19]
Wang LL, Wallis CJ, Sathianathen N, et al. ‘‘ProtecTion’’ from overtreatment: does a randomized trial finally answer the key question in localized prostate cancer? BJU Int 2017;119:513–4.
[20]
Roobol MJ, Bokhorst LP. The ProtecT trial: what can we expect? Lancet Oncol 2014;15:1046–7.
[21]
Lennernas B, Majumder K, Damber JE, et al. Radical prostatectomy versus high-dose irradiation in localized/locally advanced pros- tate cancer: a Swedish multicenter randomized trial with patient- reported outcomes. Acta Oncol 2015;54:875–81.
[22]
Wallis CJ, Saskin R, Choo R, et al. Surgery versus radiotherapy for clinically localized prostate cancer: a systematic review and meta- analysis. Eur Urol 2016;70:21–30.[23]
Albertsen PC, Hanley JA, Barrows GH, et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005;97:1248– 53.[24]
Tyson MD, Penson DF, Resnick MJ. The comparative oncologic effectiveness of available management strategies for clinically localized prostate cancer. Urol Oncol 2017;35:51–8.[25]
Roach 3rd M, Ceron Lizarraga TL, Lazar AA. Radical prostatectomy versus radiation and androgen deprivation therapy for clinically localized prostate cancer: how good is the evidence? Int J Radiat Oncol Biol Phys 2015;93:1064–70.[26] Reeves BC, Deeks JJ, Higgins JP, Wells GA. Tools for assessing
methodological quality of risk of bias in non-randomized studies.
In: Higgins JP, Green S, editors. Cochrane handbook for systematic
reviews of interventions, version 5.1.02011.
[27]
Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging con- sensus on rating quality of evidence and strength of recommen- dations. BMJ 2008;336:924–6.[28]
Sun M, Sammon JD, Becker A, et al. Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation. BJU Int 2014;113:200–8.
[29]
Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeu- len MJ. Analysis of observational studies in the presence of treat- ment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA 2007;297:278–85.[30]
Giordano SH, Kuo YF, Duan Z, Hortobagyi GN, Freeman J, Goodwin JS. Limits of observational data in determining outcomes from cancer therapy. Cancer 2008;112:2456–66.
[31]
Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Comparative risk-adjusted mortality outcomes after primary surgery, radio- therapy, or androgen-deprivation therapy for localized prostate cancer. Cancer 2010;116:5226–34.[32]
Zelefsky MJ, Eastham JA, Cronin AM, et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 2010;28:1508–13.[33]
Kishan AU, Shaikh T, Wang PC, et al. Clinical outcomes for patients with Gleason score 9-10 prostate adenocarcinoma treated with radiotherapy or radical prostatectomy: a multi-institutional com- parative analysis. Eur Urol 2017;71:766–73.[34] Phillips B, Ball C, Sackett DL, et al. Oxford Centre for Evidence-based
Medicine—levels of evidence (March 2009).
www.cebm.net/oxford- centre-evidence-based-medicine-levels-evidence-march-2009.
[35]
Sosnowski R, Kulpa M, Kosowicz M, et al. Basic methods for the assessment of the health related quality of life in uro-oncological patients. Minerva Urol Nefrol 2017;69:409–20.[36]
Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2016;375:1425–37.E U R O P E A N U R O L O G Y 7 3 ( 2 0 1 8 ) 1 1 – 2 0
18